Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 471 to 480 of 629 total matches.
Comparison Chart: Interleukin (IL) Antagonists and Oral JAK Inhibitors for Moderate to Severe Atopic Dermatitis (online only)
The Medical Letter on Drugs and Therapeutics • Mar 02, 2026 (Issue 1749)
(Sanofi/Regeneron)
200 mg/1.14 mL, 300 mg/ 2 mL prefilled pens, syringes IL-4 and IL-13 inhibitor >6 ...
View the Comparison Chart: Interleukin (IL) Antagonists and Oral JAK Inhibitors for Moderate to Severe Atopic Dermatitis
Med Lett Drugs Ther. 2026 Mar 2;68(1749):e43-4 doi:10.58347/tml.2026.1749e | Show Introduction Hide Introduction
Comparison Table: Some Drugs for Plaque Psoriasis (online only)
The Medical Letter on Drugs and Therapeutics • Sep 30, 2024 (Issue 1712)
▶ Suspension and foam can be used on
the scalpComparison Table. Some Drugs for Plaque Psoriasis (continued)1 ...
View the Comparison Table: Some Drugs for Plaque Psoriasis
Med Lett Drugs Ther. 2024 Sep 30;66(1712):e160-6 doi:10.58347/tml.2024.1712b | Show Introduction Hide Introduction
Cantharidin Topical Solution (Ycanth) for Molluscum Contagiosum
The Medical Letter on Drugs and Therapeutics • Feb 19, 2024 (Issue 1696)
been approved by the FDA for treatment of
molluscum contagiosum (in patients ≥1 year old); it
will be reviewed ...
The FDA has approved cantharidin 0.7% solution
(Ycanth – Verrica) for topical treatment of molluscum
contagiosum in patients ≥2 years old. Ycanth
was the first drug to be approved in the US for this
indication. A 10.3% gel formulation of berdazimer
(Zelsuvmi), a nitric oxide-releasing agent, has
also been approved by the FDA for treatment of
molluscum contagiosum (in patients ≥1 year old); it
will be reviewed in a future issue.
Med Lett Drugs Ther. 2024 Feb 19;66(1696):27-9 doi:10.58347/tml.2024.1696b | Show Introduction Hide Introduction
Taletrectinib (Ibtrozi) — Another Kinase Inhibitor for Non-Small Cell Lung Cancer (NSCLC) (online only)
The Medical Letter on Drugs and Therapeutics • Aug 04, 2025 (Issue 1734)
.1
Key Points: Taletrectinib (Ibtrozi)
▶ Description: An oral kinase inhibitor.
▶ Indication ...
Taletrectinib (Ibtrozi – Nuvation Bio), an oral kinase
inhibitor, has been approved by the FDA for treatment
of locally advanced or metastatic ROS1-positive non-small
cell lung cancer (NSCLC) in adults. It is the fourth
oral kinase inhibitor to be approved in the US for this
indication; crizotinib (Xalkori), entrectinib (Rozlytrek),
and repotrectinib (Augtyro) were approved earlier.
Med Lett Drugs Ther. 2025 Aug 4;67(1734):e130-1 doi:10.58347/tml.2025.1734d | Show Introduction Hide Introduction
Bemotrizinol — A New Sunscreen
The Medical Letter on Drugs and Therapeutics • Aug 03, 2026 (Issue 1760)
and UVA can cause photoaging,
hyperpigmentation, and skin cancer.1
SPF/BROAD SPECTRUM RATINGS ― The sun ...
Bemotrizinol (bis-ethylhexyloxyphenol methoxyphenol
triazine), a broad-spectrum, organic ultraviolet (UV) filter
that has been available in Europe since 2000, is the first new
active ingredient with broad availability to be added to the
FDA's OTC sunscreen monograph in more than 25 years, and
the first organic UV filter to be generally recognized as safe
and effective (GRASE). Data with other organic UV filters
are insufficient for a GRASE designation.
Med Lett Drugs Ther. 2026 Aug 3;68(1760):121-2 doi:10.58347/tml.2026.1760a | Show Introduction Hide Introduction
Comparison Table: Drugs for Alzheimer's Disease Dementia (online only)
The Medical Letter on Drugs and Therapeutics • Mar 30, 2026 (Issue 1751)
of galantamine
▶ Approval based on earlier studies with galantamine
Rivastigmine – generic
1.5, 3, 4.5, 6 mg ...
View the Comparison Table: Drugs for Alzheimer's Disease Dementia
Med Lett Drugs Ther. 2026 Mar 30;68(1751):e57-8 doi:10.58347/tml.2026.1751c | Show Introduction Hide Introduction
Treatment of Common Respiratory Tract Infections
The Medical Letter on Drugs and Therapeutics • Apr 17, 2023 (Issue 1674)
of some common respiratory tract
infections are listed in Table 1 for adults and Table 2
for children ...
Most respiratory tract infections are caused by
viruses. Bacterial respiratory tract infections are
usually treated empirically with antibiotic therapy
that targets the most probable causative pathogens.
Recommended antibiotic regimens for outpatient
treatment of some common respiratory tract
infections are listed in Table 1 for adults and Table 2
for children.
Med Lett Drugs Ther. 2023 Apr 17;65(1674):57-62 doi:10.58347/tml.2023.1674a | Show Introduction Hide Introduction
In Brief: Edaravone Oral Suspension (Radicava ORS) for ALS (online only)
The Medical Letter on Drugs and Therapeutics • Sep 05, 2022 (Issue 1658)
) has been
available since 2017.1
CLINICAL STUDIES — No new clinical trials were
required for FDA approval of oral ...
Radicava ORS, an oral suspension formulation of
the free radical scavenger edaravone (Mitsubishi
Tanabe Pharma), has been approved by the FDA for
treatment of amyotrophic lateral sclerosis (ALS). An
IV formulation of edaravone (Radicava) has been
available since 2017.
Apoaequorin (Prevagen) to Improve Memory
The Medical Letter on Drugs and Therapeutics • Nov 01, 2021 (Issue 1636)
protein found in humans.1
Dysregulation of neuronal calcium is thought to be
involved in the complex ...
A synthetic form of the protein apoaequorin is the
active ingredient in the over-the-counter dietary
supplement Prevagen (Quincy Bioscience), which
is heavily marketed to improve memory.
In Brief: Afamitresgene Autoleucel (Tecelra) for Synovial Sarcoma (online only)
The Medical Letter on Drugs and Therapeutics • Oct 14, 2024 (Issue 1713)
autoleucel was based on the results of an open-label
trial (SPEARHEAD-1) in 44 HLA-A*02:01-03 and 06
allele ...
Afamitresgene autoleucel (Tecelra – Adaptimmune),
a melanoma-associated antigen A4 (MAGE-A4)-directed genetically modified autologous T-cell
immunotherapy, has received accelerated approval
from the FDA for one-time treatment of adults with
unresectable or metastatic synovial sarcoma who
received prior chemotherapy and are HLA-A*02:01P,
-A*02:02P, -A*02:03P, or -A*02:06P positive and
whose tumor expresses the MAGE-A4 antigen. It is
the first gene therapy to be approved in the US for
treatment of synovial sarcoma. Accelerated approval
of the immunotherapy was based on the...
Med Lett Drugs Ther. 2024 Oct 14;66(1713):e169-70 doi:10.58347/tml.2024.1713i | Show Introduction Hide Introduction
